AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).
AstraZeneca has had a setback to its ambitions in diabetes, after Bydureon failed to show cardiovascular benefits to patients. The FDA now obliges companies with diabetes products to conduct large ...